There is now evidence for both increased and decreased activity of the enzymes controlling the methylation of lysine 27 on histone 3 (H3K27) in cancer. One of these enzymes, KDM6B formally known as JMJD3, a histone demethylase, which removes the trimethyl mark from H3K27, is required for the lineage commitment and terminal differentiation of neural stem cells and of keratinocytes. Our results suggest that KDM6B may also have a role in antigen-driven B-cell differentiation. KDM6B expression increases in B-cell subsets with increasing stage of differentiation, and gene expression profiling shows that KDM6B transcriptional targets in germinal centre B (GC B) cells are significantly enriched for those differentially expressed during memory and plasma cell differentiation. Our results also suggest that aberrant expression of KDM6B may contribute to the pathogenesis of Hodgkin's Lymphoma (HL), an Epstein-Barr virus (EBV) associated malignancy. KDM6B is over-expressed in primary HL and induced by the EBV oncogene, latent membrane protein (LMP1) in GC B cells, the presumptive progenitors of HL. Consistent with these observations, we found that KDM6B transcriptional targets in GC B cells are enriched for genes differentially expressed in HL, and that KDM6B depletion can restore the tri-methylation of H3K27 on these genes.
Introduction
Post-translational modification of histone tails alters the physical state of chromatin and has an essential role in both transcriptional repression and activation during embryonic development, lineage specification and terminal differentiation. One such repressive modification, the tri-methylation of lysine 27 on histone H3 (H3K27me3), is catalysed by the polycomb group protein, EZH2 (Simon and Lange, 2008) . KDM6B is one of only two demethylases known to remove the tri-methyl mark from H3K27, the other is UTX (Agger et al., 2007; Hong et al., 2007) . These demethylases reverse polycomb group-mediated transcriptional repression by demethylating H3K27me3 and dissociating polycomb group complexes (Agger et al., 2009; Agherbi et al., 2009; Barradas et al., 2009) . Both KDM6B and UTX are necessary for the lineage commitment of embryonic stem cells and for the terminal differentiation of progenitor cells. KDM6B, for example, is required for the commitment of embryonic stem cells to the neural lineage, and for the terminal differentiation of neural stem cells and of dermal keratinocytes (Jepsen et al., 2007; Burgold et al., 2008; Sen et al., 2008; Dai et al., 2010; Fei et al., 2010) . There is now evidence that both increased and decreased activity of enzymes controlling H3K27 methylation contributes to carcinogenesis. Both EZH2 and UTX are reported to be mutated in cancer and KDM6B has been shown to be upregulated by the human papillomavirus E7 oncoprotein (Holland et al., 2008; Morin et al., 2010; Haaften et al., 2010) . We now investigate if KDM6B expression can be modulated by another oncogenic virus, Epstein-Barr virus (EBV), which has been implicated in the development of GC B-cell-derived malignancies, including Burkitt's lymphoma, Hodgkin's lymphoma (HL) and post-transplant lymphoma. We focus on the major EBV transforming gene, latent membrane protein 1 (LMP1), which can be detected in B50% of cases of primary HL. As LMP1 has been shown to hijack the B-cell transcriptional programme and to subvert normal B-cell differentiation, we assess the contribution to the transcriptional changes associated with abnormal B-cell development of LMP1-induced regulation of the H3K27 demethylase, KDM6B (Vockerodt et al., 2008) .
Results
KDM6B is differentially expressed in B-cell subsets and its transcriptional profile overlaps that of the B-cell differentiation program We first measured, how the expression of the two H3K27 demethylases, KDM6B and UTX, and that of the histone methyltransferase, EZH2, varied in preand post-GC B-cell subsets of tonsillar lymphocytes. Although the expression of UTX did not vary significantly across these subsets, that of EZH2 was lowest in memory B cells and highest in centroblasts. In contrast, the expression of KDM6B was lowest in centroblasts and highest in memory B cells (Figure 1) .
To identify the transcriptional targets of KDM6B, gene expression profiling was performed on CD10 þ GC B cells transfected with KDM6B, the over-expression of which was confirmed by immunoblotting ( Figure 2 ). Transfection was followed in at least two of three tonsils by the upregulation of 161 unique named genes, and the downregulation of 281 genes (Supplementary Table 1 ). These genes were significantly enriched for those reported to be differentially expressed in plasma cells and in memory cells when compared with centrocytes suggesting that KDM6B may have a role in B-cell differentiation (Table 1; Brune et al., 2008) .
EBV and LMP1 upregulate expression of KDM6B in primary B cells We next explored whether EBV infection induced changes in the expression of KDM6B in B cells. As there is no compelling evidence to suggest that EBV directly infects GC B cells, we chose as our in vitro model, EBV-infected CD19 þ peripheral blood mononuclear B cells, because they exclusively contain both memory and naive B cells which are likely to be the primary targets of EBV infection in vivo. Three days following infection, KDM6B was found to be upregulated at the transcriptional and protein level (Figures 3a-c) . As the upregulation of KDM6B appeared to coincide with the first detection of LMP1 (Figures 3b and c) , we investigated whether KDM6B expression was regulated by this viral oncogene in tonsillar CD10 þ GC B cells, the presumptive progenitors of HL. We found that KDM6B was upregulated by LMP1 in these cells ( Figure 3d ); this was a consistent finding in cells isolated from different donors. It was also consistent with the results of our published array, which had suggested that LMP1 transcriptionally upregulates KDM6B in GC B cells, but not EZH2 or KDM6A, two other enzymes known to modulate H3K27 tri-methylation (Vockerodt et al., 2008) . In line with our finding that LMP1-induced upregulation of KDM6B, we established that KDM6B transcriptional targets identified in our array analysis were significantly enriched for genes, which we have previously reported to be differentially expressed in LMP1-transfected GC B cells (Table 1; Vockerodt et al., 2008) . Quantitative-PCR confirmed the transcriptional upregulation by KDM6B of five candidate genes, which had been shown to be upregulated by both KDM6B and LMP1 in our array analyses (Figure 4) . KDM6B is over-expressed in primary HL and its transcriptional profile overlaps that of HL The expression of KDM6B was examined using immunohistochemistry in 30 cases of primary HL, illustrative examples are shown in Figure 5 . Compared with surrounding tissue, KDM6B expression was strongly expressed in malignant Hodgkin/Reed-Sternberg cells in 16 (53%) cases, with high levels of expression found in both EBV þ and EBVÀ tumours (63% vs 43%, Supplementary Table 2) .
We next investigated KDM6B associated changes in the H3K27me3 mark in HL. Having successfully reduced expression of KDM6B in the HL cell line, L428, using small interfering RNA (Figure 6a ), changes in H3K27me3 levels were measured in two genes, CD58 and NOTCH2NL. These genes were selected because we had shown that they are KDM6B transcriptional targets in GC B cells (Figure 4 ), and they are reported to be T1 T2
Immunoblot showing expression of transfected KDM6B in purified GC B cells isolated from two tonsils (T1 and T2). KDM6B-HA fusion protein was detected in unsorted transfected cell lysates using an a-HA antibody and an a-MCM7 as a loading control.
upregulated in HL (Sandvej et al., 1993; Brune et al., 2008) . Knockdown of KDM6B in L428 cells was followed by a substantial increase in the deposition of H3K27me3 on both genes ( Figure 6b ).
Discussion
KDM6B has a critical role in the terminal differentiation of neural stem cells and of dermal keratinocytes.
Our results suggest that it also has a role in antigendriven B-cell differentiation. Whereas the expression of KDM6B, which removes the tri-methyl mark from H3K27 mark increases in B-cell subsets with their increasing differentiation, that of EZH2, which imposes this mark falls, in line with previous reports (Raaphorst et al., 2000) . The expression of the only other known H3K27 demethylase, UTX, did not vary across these cell types. Consistent with these observations, we found that KDM6B transcriptional targets in GC B cells are significantly enriched for genes differentially expressed during B-cell differentiation. Confirmation of the causal nature of this relationship will be dependent on the investigation of B-cell differentiation using in vivo models in which KDM6B function has been disrupted.
Our results also suggest that the aberrant expression of KDM6B may contribute to the pathogenesis of HL. First, we have shown that the oncoprotein, LMP1, which is expressed in B50% of HL, induces KDM6B expression in GC B cells. Our findings are consistent with those of a published array, which suggested that the expression of a conditional LMP1 allele in EBV-infected B cells is followed by the early upregulation of KDM6B (Dirmeier et al., 2005, Supplementary Information ).
As we have already shown that LMP1 can disrupt the normal B-cell differentiation programme driving it towards a post-GC stage, and as the ectopic expression of KDM6B has been shown to induce differentiation in other systems, then LMP1-induced disruption of normal B-cell differentiation could be explained in part by its induction of KDM6B (Sen et al., 2008; Vockerodt et al., 2008) . It also remains to be determined how EBVinduced expression of KDM6B contributes to the differentiation dependent EBV life-cycle. However, the ectopic expression of KDM6B in cell lines infected with another gamma herpes virus, Kaposi's sarcoma-associated herpesvirus is followed by the upregulation of the viral gene ORF50. ORF50, which orchestrates the expression of lytic genes leading to viral amplification is a homolog of the EBV transactivator, BRLF1 (Rta) (Gu¨nther and Grundhoff, 2010) . These observations suggest that in gamma herpesviruses, the latent/lytic switch may be dependent not only on the dynamics of DNA methylation on early viral promoters, but also on changes in the distribution of the H3K27me3 mark. (T1 and T2 ). It should be pointed out that CD58 differs from the other candidate genes in so far as its baseline expression varied substantially (78-fold) across the two tonsils. However, this difference was only 2.7-fold when post-transfection expression levels were compared. Figure 5 Expression of KDM6B in primary HL; tissue sections were stained with a rabbit polyclonal antibody to KDM6B (original magnification Â 600).
We also found that KDM6B is over-expressed in the Hodgkin/Reed-Sternberg cells of 53% of primary HL. However, its over-expression in tumours, which test negative for EBV points to additional regulatory mechanisms. NFkB is constitutively activated in both EBV positive and in EBV negative tumours, and has been shown to regulate the expression of KDM6B in macrophages (De Santa et al., 2007; Aldinucci et al., 2010) . However, we found no evidence to suggest that NFkB regulates KDM6B expression in HL cells (Supplementary Figure 1) , consistent with reports that NFkB is not involved in oncogene or stress-induced upregulation of KDM6B in human diploid fibroblasts (Agger et al., 2009) . Other candidates known to be deregulated in HL may merit investigation, for example, STAT6, which mediates IL4-dependent KDM6B expression in macrophages is also constitutively activated in HL (Skinnider et al., 2002; Mainou-Fowler, 2004; Ishii et al., 2009) .
KDM6B depletion in HL cells rescued H3K27me3 levels on genes, which are KDM6B transcriptional targets in GC B cells and which are differentially expressed in HL. Although increased H3K27me3 levels were not associated with the transcriptional downregulation of these candidate genes, uncoupling of methylation and transcriptional change following KDM6B depletion has also been reported in other systems (Burgold et al., 2008; De Santa et al., 2009) . Adding another layer of complexity, genome-wide analyses have revealed that most KDM6B transcriptional targets in LPS-activated macrophages are not marked by H3K27me3 suggesting that in some circumstances at least, KDM6B-induced transcriptional changes are not dependent on the removal of the trimethyl mark (De Santa et al., 2009) . Notwithstanding these uncertainties about the mechanisms of action of KDM6B, our array analysis which revealed that KDM6B transcriptional targets are significantly enriched for genes which are differentially expressed in HL, provides the final and perhaps most compelling evidence that LMP1-induced expression of KDM6B contributes to the pathogenesis of HL.
Materials and methods

Purification of human tonsillar B-cell subsets
Human tonsils were obtained from paediatric patients after informed consent had been provided (ethical approval reference number: 06/Q2702/50). Tonsillar mononuclear cells were isolated by Ficol-Isopaque centrifugation and then enriched for CD77 þ centroblasts by incubation with anti-CD77 antibody (Becton Dickinson, Franklin Lakes, NJ, USA) and with anti-IgM microbeads, followed by magnetic separation on LS columns (Miltenyi Biotec, Du¨sseldorf, Germany). The remaining CD77À population was enriched for CD10 þ centrocytes by incubation with PE-conjugated anti-CD10 (Becton Dickinson) and anti-PE microbeads, followed by separation on LS columns. Naı¨ve B cells were isolated indirectly from mononuclear cells by depletion of all nonnaı¨ve cells using a cocktail of antibodies to CD10, CD2, CD16, CD27, CD36, CD43 and CD235a (Miltenyi Biotec). Memory B cells were first purified by negative depletion using antibodies against CD2, CD14, CD16, CD36, CD43 and CD235a, and then positively selected using CD27 microbeads (Miltenyi Biotec).
EBV infection CD19 þ primary B cells were isolated from peripheral blood, according to standard methods (Shannon-Lowe et al., 2005) . Preparations of wild-type virus (EBV 2089) were made from HEK 293 cells carrying a recombinant B95.8 EBV genome and a BALF4-expression plasmid used to optimise Gp110 levels (Delecluse et al., 1998; Neuhierl et al., 2002) . Quantitative-PCR was used to quantify virus copy number in cell-free virus preparations, following which primary B cells were incubated overnight with EBV at a multiplicity of infection of 100 genomes/cell. Cells were washed to remove unbound virus and cultured in RPMI-1640 medium supplemented with 10% foetal calf serum.
Purification and transfection of GC B cells
Tonsillar CD10 þ germinal centre B (GC B) cells at a concentration of 1 Â 10 7 cells in 100 ml of B-cell solution (Lonza, Basel, Switzerland) were co-transfected with 3 mg of pMACS-LNGFR (Miltenyi Biotec) and 7 mg of either pCMVor pCMV-HA-KDM6B-expression vector (Agger et al., 2007) using program U15 on the Nucleofector (Lonza). Following overnight cultivation, transfected cells were isolated by staining with anti-LNFGR-FITC (Miltenyi Biotec) and propidium iodide, following which FITC-labelled propidium iodide-negative cells were collected on a MoFlo fluorescence cell sorter (Dako, Glostrup, Denmark) .
Microarray experiments and comparisons
The total RNA provided by three separate donors was first extracted from fluorescence-activated cell sorting-sorted transfected GC B cells as described above, and then amplified with the ExpressArt mRNA Amplification kit protocol (AmpTec, Hamburg, Germany). Fragmented and labelled cRNA (10 mg) was hybridised to HG-U133Plus2 microarrays. Microarray chips were analysed using GCOS Software from Affymetrix Inc. (Santa Clara, CA, USA) . Genes were considered to be differentially expressed following KDM6B transfection when they were found to be significantly changed in two or more tonsils using the Affymetrix MAS5 pair-wise comparison method of analysis. The results of our KDM6B-GC B arrays were compared with published arrays reporting either LMP1-transcriptional targets in GC B cells or genes, which were differentially expressed in plasma cells or memory cells, or both, when compared with centrocytes (Brune et al., 2008; Vockerodt et al., 2008) . The primary data are available from GEO (http://www.ncbi.nlm.nih.gov/geo/) under series accession No GSE24044.
Western blotting and immunohistochemistry
The antibodies used for western blot analysis and immunohistochemistry were a rabbit polyclonal to KDM6B (Agger et al., 2009) ; rabbit anti-HA (Santa Cruz, Santa Cruz, CA, USA); mouse anti-LMP1 (Dako); mouse anti-MCM-7 (SigmaAldrich, St Louis, MO, USA) and rabbit anti-calregulin (Sigma-Aldrich) were used as loading controls. Immunohistochemistry was performed on formalin-fixed paraffin embedded tissue. After antigens had been retrieved by overnight incubation in EDTA 1mM (pH 8.0)/Tween 20 (0.1%) buffer at 651C, slides were incubated with anti-KDM6B for 1 h and bound antibody detected using the Envision IHC Select kit (Dako).
RNA interference KDM6B expression was silenced in the HL cell line, L428, using pre-designed SMARTpool RNA oligonuclotides (Dharmacon, Waltham, MA, USA). Cells (5 Â 10 5 ) were nucleofected with 3mg KDM6B small interfering RNA or a randomly generated non-targeting small interfering RNA in 100ml of nucleofection solution L (Lonza), and cultured for 48 h before harvesting.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed on the HL cell line, L428; 0.5 Â 10 6 cells were formalin-fixed, lysed and then sonicated using a Diagenode Biorupter (7 min, medium power). Chromatin (10 mg) was used for immunoprecipitation using protein G Dynabeads (Invitrogen, Carlsbad, CA, USA) and anti-H3K27me3 antibody (Upstate Biotechnology, Waltham, MA, USA). Primer sequences and a detailed protocol are available on request.
Inhibition of nuclear factor kappa B activity Nuclear factor kappa B activity was inhibited in L428 cells using an expression vector, which encodes a mutant super repressor form of IkBa in which alanine residues are substituted for serine at positions 32 and 36 (Hellerbrand et al., 1998) . Cells (1 Â 10 7 ) were electroporated with 7 mg pMACs 4.1 vector expressing CD4 and 14 mg of either the IkBa super repressor or a control vector (pcDNA3). Transfected cells were isolated after 48 h by magnetic bead separation using anti-CD4 antibody on MS columns (Miltenyi Biotec). To confirm inhibition of this pathway, flow cytometry analysis was used to measure the expression of intercellular adhesion molecule 1, a known target of nuclear factor kappa B signalling (Ledebur and Parks, 1995) .
Quantitative-PCR RNA was isolated using the Rneasy Mini kit or Micro kit (Qiagen, Du¨sseldorf, Germany) and complementary DNA was prepared using AMV reverse transcriptase (Invitrogen) with a random hexamer primer (Promega, Madison, WI, USA). The complementary DNA samples were analyzed in triplicate using TaqMan Universal PCR Master Mix on a ABI 7500 Fast realtime PCR system according to the manufacturer's instructions (Applied Biosystems, Carlsbad, CA, USA). Data were analyzed with 7500 Fast System SDS software 1.3.1 (Applied Biosystems), and the TaqMan 2-DD CT method was used to quantify mRNA expression relative to B2M as a housekeeping control.
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